Crinetics Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Checking your notes…
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Crinetics Pharmaceuticals, Inc. | ||
| Date: February 27, 2025 | By: | /s/ R. Scott Struthers, Ph.D. |
|---|---|---|
| R. Scott Struthers, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ R. Scott Struthers, Ph.D. | President, Chief Executive Officer and Director | February 27, 2025 |
| R. Scott Struthers, Ph.D. | (principal executive officer) | |
| /s/ Marc J.S. Wilson | Chief Financial Officer | February 27, 2025 |
| Marc J.S. Wilson | (principal financial and accounting officer) | |
| /s/ Wendell Wierenga, Ph.D. | Chairman of the Board of Directors | February 27, 2025 |
| Wendell Wierenga, Ph.D. | ||
| /s/ Camille Bedrosian, M.D. | Director | February 27, 2025 |
| Camille Bedrosian, M.D. | ||
| /s/ Caren Deardorf | Director | February 27, 2025 |
| Caren Deardorf | ||
| /s/ Matthew K. Fust | Director | February 27, 2025 |
| Matthew K. Fust | ||
| /s/ Weston Nichols, Ph.D. | Director | February 27, 2025 |
| Weston Nichols, Ph.D. | ||
| /s/ Stephanie Okey | Director | February 27, 2025 |
| Stephanie Okey | ||
| /s/ Rogério Vivaldi Coelho, M.D. | Director | February 27, 2025 |
| Rogério Vivaldi Coelho, M.D. | ||
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.